AIDS and Behavior

, Volume 14, Issue 6, pp 1269–1278 | Cite as

Substance Use in HIV-Infected Women During Pregnancy: Self-Report Versus Meconium Analysis

  • Katherine Tassiopoulos
  • Jennifer S. Read
  • Susan Brogly
  • Kenneth Rich
  • Barry Lester
  • Stephen A. Spector
  • Ram Yogev
  • George R. SeageIII
Article

Abstract

We evaluated prenatal substance use in a cohort of 480 HIV-infected women and their uninfected children. Substance use was reported by 29%; the most common substances reported were tobacco (18%), alcohol (10%), and marijuana (7.2%). Fewer than 4% of women reported cocaine or opiate use. Substance use was more common in the first trimester (25%) than the second (17%) and third (15%) (trend p-value <0.01), and was associated with race/ethnicity, education, birthplace, age and marital status. For 264 mother/infant pairs with meconium results, sensitivity of self-report was 86% for tobacco, 80% for marijuana and 67% for cocaine. Higher discordance between self-report and urine/blood toxicology was observed for cocaine, marijuana and opiates in a non-random subset of mothers/infants with these tests. Findings suggest reasonably complete self-reporting of substance use as confirmed by meconium analysis. Illicit substance use was low and substantially less than that reported in earlier studies of HIV-infected women, but alcohol and tobacco exposure was prevalent.

Keywords

Substance use Prenatal exposure Meconium HIV 

Notes

Acknowledgements

We thank the children and families for their participation in the PHACS protocol “Surveillance Monitoring for ART Toxicities” (SMARTT), and the individuals and institutions involved in the conduct of PHACS SMARTT. The study was supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development with co-funding from the National Institute of Allergy and Infectious Diseases, the National Institute on Drug Abuse, the National Institute of Mental Health, National Institute of Deafness and Other Communication Disorders, the National Heart Lung and Blood Institute, National Institute of Neurological Disorders and Stroke, and the National Institute on Alcohol Abuse and Alcoholism, through cooperative agreements with the Harvard University School of Public Health (U01 HD052102-04) (Principal Investigator: George Seage; Project Director: Julie Alperen) and the Tulane University School of Medicine (U01 HD052104-01) (Principal Investigator: Russell Van Dyke; Co-Principal Investigator: Kenneth Rich; Project Director: Patrick Davis). Data management services were provided by Frontier Science and Technology Research Foundation (PI: Suzanne Siminski), and regulatory services and logistical support were provided by Westat, Inc (PI: Mercy Swatson).

References

  1. 1.
    Day N, Richardson G, Geva D, Robles N. Alcohol, marijuana, and tobacco: effects of prenatal exposure on offspring growth and morphology at age six. Alcohol Clin Exp Res. 2006;18(4):786–94.CrossRefGoogle Scholar
  2. 2.
    Fox N, Sexton M, Hebel JR. Prenatal exposure to tobacco. I. Effects on physical growth at age three. Int J Epidemiol. 1990;19(1):66–71.CrossRefPubMedGoogle Scholar
  3. 3.
    Lightwood J, Phibbs C, Glantz S. Short-term health and economic benefits of smoking cessation: low birth weight. Pediatrics. 1999;104(6):1312–20.CrossRefPubMedGoogle Scholar
  4. 4.
    Cornelius M, Goldschmidt L, DeGenna N, et al. Smoking during teenage pregnancies: effects on behavioral problems in offspring. Nicotine Tob Res. 2007;9(7):739–50.CrossRefPubMedGoogle Scholar
  5. 5.
    Pickett K, Wood C, Adamson J, et al. Meaningful differences in maternal smoking behaviour during pregnancy: implications for infant behavioural vulnerability. J Epidemiol Community Health. 2008;62(4):318–24.CrossRefPubMedGoogle Scholar
  6. 6.
    Stroud L, Paster R, Goodwin M, et al. Maternal smoking during pregnancy and neonatal behavior: a large-scale community study. Pediatrics. 2009;123(5):e842–8.CrossRefPubMedGoogle Scholar
  7. 7.
    Weitzman M, Byrd RS, Aligne CA, Moss M. The effects of tobacco exposure on children’s behavioral and cognitive functioning: implications for clinical and public health policy and future research. Neurotoxicol Teratol. 2002;24(3):397–406.CrossRefPubMedGoogle Scholar
  8. 8.
    Cornelius M, Ryan C, Day N, Goldschmidt L, Willford J. Prenatal tobacco effects on neuropsychological outcomes among preadolescents. J Dev Behav Pediatr. 2001;22(4):217–25.PubMedGoogle Scholar
  9. 9.
    Lassen K, Oel T. Effects of maternal cigarette smoking during pregnancy on long-term physical and cognitive parameters of child development. Addict Behav. 1998;23(5):635–53.CrossRefPubMedGoogle Scholar
  10. 10.
    Riley EP, McGee CL. Fetal alcohol spectrum disorders: an overview with emphasis on changes in brain and behavior. Exp Biol Med. 2005;230(6):357–65.Google Scholar
  11. 11.
    Sampson PD, Streissguth AP, Bookstein FL, et al. Incidence of fetal alcohol syndrome and prevalence of alcohol-related neurodevelopmental disorder. Teratology. 1997;56:317–26.CrossRefPubMedGoogle Scholar
  12. 12.
    Sexton M, Fox NL, Hebel JR. Prenatal exposure to tobacco: II. Effects on cognitive functioning at age three. Int J Epidemiol. 1990;19(1):72–7.CrossRefPubMedGoogle Scholar
  13. 13.
    Bateman DA, Ng SK, Hansen CA, Heagarty MC. The effects of intrauterine cocaine exposure in newborns. Am J Public Health. 1993;83(2):190–3.CrossRefPubMedGoogle Scholar
  14. 14.
    Day N, Richardson G, Goldschmidt L, et al. Effect of prenatal marijuana exposure on the cognitive development of offspring at age three. Neurotoxicol Teratol. 1994;16(2):169–75.CrossRefPubMedGoogle Scholar
  15. 15.
    Goldschmidt L, Day NL, Richardson GA. Effects of prenatal marijuana exposure on child behavior problems at age 10. Neurotoxicol Teratol. 2000;22(3):325–36.CrossRefPubMedGoogle Scholar
  16. 16.
    Goldschmidt L, Richardson G, Willford J, Day N. Prenatal marijuana exposure and intelligence test performance at age 6. J Am Acad Child Adolesc Psychiatry. 2008;47(3):254–63.CrossRefPubMedGoogle Scholar
  17. 17.
    Leech SL, Richardson GA, Goldschmidt L, Day NL. Prenatal substance exposure: effects on attention and impulsivity of 6-year-olds. Neurotoxicol Teratol. 1999;21(2):109–18.CrossRefPubMedGoogle Scholar
  18. 18.
    Richardson GA, Goldschmidt L, Larkby C. Effects of prenatal cocaine exposure on growth: a longitudinal analysis. Pediatrics. 2007;120(4):e1017–27.CrossRefPubMedGoogle Scholar
  19. 19.
    Zuckerman B, Frank DA, Hingson R, Amaro H, Levenson S, Kayne H. Effects of maternal marijuana and cocaine use on fetal growth. N Engl J Med. 1989;320(12):762–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Levine T, Liu J, Das A, et al. Effects of prenatal cocaine exposure on special education in school-aged children. Pediatrics. 2008;122(1):e83–91.CrossRefPubMedGoogle Scholar
  21. 21.
    Bauer C, Langer J, Shankaran S, et al. Acute neonatal effects of cocaine exposure during pregnancy. Arch Pediatr Adolesc Med. 2005;159(9):824–34.CrossRefPubMedGoogle Scholar
  22. 22.
    Brinkman K, Kakuda TN. Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: a looming obstacle for long-term antiretroviral therapy? Curr Opin Infect Dis. 2000;13:5–11.PubMedGoogle Scholar
  23. 23.
    McComsey G, Lonergan JT. Mitochondrial dysfunction: patient monitoring and toxicity management. J Acquir Immune Defic Syndr. 2004;37(Suppl 1):S30–5.PubMedGoogle Scholar
  24. 24.
    Barret B, Tardieu M, Rustin P, et al. Persistent mitochondrial dysfunction in HIV-1-exposed but uninfected infants: clinical screening in a large prospective cohort. AIDS. 2003;17(12):1769–85.CrossRefPubMedGoogle Scholar
  25. 25.
    Brogly SB, Ylitalo N, Mofenson LM, et al. In utero nucleoside reverse transcriptase inhibitor exposure and signs of possible mitochondrial dysfunction in HIV-uninfected children. AIDS. 2007;21(8):928–38.CrossRefGoogle Scholar
  26. 26.
    El-Mohandes A, Herman A, Nabil E, Katta P, White D, Grylack L. Prenatal care reduces the impact of illicit drug use on perinatal outcomes. J Perinatol. 2003;23(5):354–60.CrossRefPubMedGoogle Scholar
  27. 27.
    Tello M, Yeh HC, Keller J, Beach M, Anderson J, Moore R. HIV Women’s Health: a study of gynecological healthcare service utilization in a U.S. urban clinic population. J Womens Health. 2008;17(10):1609–14.CrossRefGoogle Scholar
  28. 28.
    Cocroft JR, Hauck WW, Cosler L, Turner BJ. The effect of ethnicity and maternal birthplace on small-for-gestational-age deliveries to HIV-infected women. J Urban Health. 2002;79(1):147–60.PubMedGoogle Scholar
  29. 29.
    Rodriguez EM, Mofenson LM, Chang BH, et al. Association of maternal drug use during pregnancy with maternal HIV culture positivity and perinatal HIV transmission. AIDS. 1996;10(3):273–82.CrossRefPubMedGoogle Scholar
  30. 30.
    Schulte J, Dominguez K, Sukalac T, Bohannon B, Fowler MG, Pediatric Spectrum of HIV Disease Consortium. Declines in low birth weight and preterm birth among infants who were born to HIV-infected women during an era of increased use of maternal antiretroviral drugs: pediatric spectrum of HIV disease, 1989–2004. Pediatrics. 2007;119(4):e900–6.CrossRefPubMedGoogle Scholar
  31. 31.
    Turpin DB, Frederick MM, Matthews YL, et al. HIV infection in pregnant women: 12-year trends in the Women and Infants Transmission Study (WITS). Abstract no. T3-B1201. Paper presented at National HIV Prevention Conference, Atlanta, GA; 2003.Google Scholar
  32. 32.
    Fendrich M, Johnson T, Wislar J, Hubbell A, Spiehler V. The utility of drug testing in epidemiological research: results from a general population survey. Addiction. 2004;99(2):197–208.CrossRefPubMedGoogle Scholar
  33. 33.
    Chermack S, Roll J, Reilly M, Davis L, Kilaru U, Grabowski J. Comparisons of patient self-reports and urinalysis results obtained under naturalistic methadone treatment conditions. Drug Alcohol Depend. 2000;59(1):43–9.CrossRefPubMedGoogle Scholar
  34. 34.
    Tassiopoulos K, Bernstein J, Heeren T, Levenson S, Hingson R, Bernstein E. Predictors of disclosure of continued cocaine use. Addict Behav. 2006;31(1):80–9.CrossRefPubMedGoogle Scholar
  35. 35.
    Frank DA, Zuckerman BS, Amaro H, et al. Cocaine use during pregnancy: prevalence and correlates. Pediatrics. 1988;82(6):888–95.PubMedGoogle Scholar
  36. 36.
    Lester BM, elSohly MA, Wright LL, et al. The Maternal Lifestyle Study: drug use by meconium toxicology and maternal self-report. Pediatrics. 2001;107(2):309–17.CrossRefPubMedGoogle Scholar
  37. 37.
    Ostrea EM, Brady MJ, Gauase S, Raymundo AL, Stevens M. Drug screening of newborns by meconium analysis: a large scale, prospective, epidemiologic study. Pediatrics. 1992;89(1):107–13.PubMedGoogle Scholar
  38. 38.
    Della Grotta S, Lagasse LL, Arria AM, et al. Patterns of methamphetamine use during pregnancy: results from the Infant Development, Environment, and Lifestyle (IDEAL) Study. Matern Child Health J. 2009 [Epub ahead of print].Google Scholar
  39. 39.
    Ostrea EM, Knapp DK, Tannenbaum L, et al. Estimates of illicit drug use during pregnancy by maternal interview, hair analysis, and meconium analysis. J Pediatr. 2001;138(3):344–8.CrossRefPubMedGoogle Scholar
  40. 40.
    Abma JC, Mott FL. Substance use and prenatal care during pregnancy among young women. Fam Plann Perspect. 1991;23(3):117–28.CrossRefPubMedGoogle Scholar
  41. 41.
    Jesse DE, Graham M, Swanson M. Psychosocial and spiritual factors associated with smoking and substance use during pregnancy in African American and Caucasian low-income women. J Obstet Gynecol Neonatal Nurs. 2006;35(1):68–77.CrossRefPubMedGoogle Scholar
  42. 42.
    Martin L, English KT, Clark KA, Cilenti D, Kupper LL. Violence and substance use among North Carolina pregnant women. Am J Public Health. 1996;86(7):991–8.CrossRefPubMedGoogle Scholar
  43. 43.
    Katz I, Shapiro R, Li Daner, et al. Risk factors for detectable HIV-1 RNA at delivery among women receiving highly active antiretroviral therapy in the Women and Infants Transmission Study. JAIDS. 2010 [Epub ahead of print].Google Scholar
  44. 44.
    Derauf C, Katz A, Frank D, Grandinetti A, Easa D. The prevalence of methamphetamine and other drug use during pregnancy in Hawaii. J Drug Issues. 2003;33(4):1001–16.Google Scholar
  45. 45.
    Baden L, Horowitz G, Jacoby H, Eliopoulos G. Quinolones and false-positive urine screening for opiates by immunoassay technology. JAMA. 2001;286(24):3115–9.CrossRefPubMedGoogle Scholar
  46. 46.
    Zacher J, Givone D. False-positive urine opiate screening associated with fluoroquinolone use. Ann Pharmacother. 2004;38(9):1525–8.CrossRefPubMedGoogle Scholar
  47. 47.
    Gatzke-Kopp LM, Beauchaine TP. Direct and passive prenatal nicotine exposure and the development of externalizing psychopathology. Child Psychiatry Hum Dev. 2007;38(4):255–69.CrossRefPubMedGoogle Scholar
  48. 48.
    Windham GC, Hopkins B, Fenster L, Swan SH. Prenatal active or passive tobacco smoke exposure and the risk of preterm delivery or low birth weight. Epidemiology. 2000;11(4):427–33.CrossRefPubMedGoogle Scholar
  49. 49.
    Frank DA, Augustyn M, Knight WG, Pell T, Zuckerman B. Growth, development, and behavior in early childhood following prenatal cocaine exposure: a systematic review. JAMA. 2001;285(12):1613–25.CrossRefPubMedGoogle Scholar
  50. 50.
    Manning M, Eugene H. Fetal alcohol spectrum disorders: a practical clinical approach to diagnosis. Neurosci Biobehav Rev. 2007;31(2):230–8.CrossRefPubMedGoogle Scholar
  51. 51.
    Rivkin M, Davis P, Lemaster J, et al. Volumetric MRI study of brain in children with intrauterine exposure to cocaine, alcohol, tobacco, and marijuana. Pediatrics. 2008;121(4):741–50.CrossRefPubMedGoogle Scholar
  52. 52.
    Kalichman S, Amaral C, White D, et al. Prevalence and clinical implications of interactive toxicity beliefs regarding mixing alcohol and antiretroviral therapies among people living with HIV/AIDS. AIDS Patient Care STDS. 2009;23(6):449–54.CrossRefPubMedGoogle Scholar
  53. 53.
    Samet J, Horton N, Traphagen E, Lyon S, Freedberg K. Alcohol consumption and HIV disease progression: are they related? Alcohol Clin Exp Res. 2003;27(5):862–7.CrossRefPubMedGoogle Scholar
  54. 54.
    Moore C, Jones J, Lewis D, Buchi K. Prevalence of fatty acid ethyl esters in meconium specimens. Clin Chem. 2003;49(1):133–6.CrossRefPubMedGoogle Scholar
  55. 55.
    Ernhart CB, Morrow-Tlucak M, Sokol RJ, Martier S. Underreporting of alcohol use in pregnancy. Alcohol Clin Exp Res. 1998;12(4):506–11.CrossRefGoogle Scholar
  56. 56.
    Substance Abuse and Mental Health Services Administration, Office of Applied Studies. The NSDUH Report: substance use among women during pregnancy and following childbirth. Rockville, MD. May 21, 2009.Google Scholar
  57. 57.
    Flanagan P, Kokotailo P. Adolescent pregnancy and substance use. Clin Perinatol. 1999;26(1):185–200.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Katherine Tassiopoulos
    • 1
  • Jennifer S. Read
    • 2
  • Susan Brogly
    • 3
  • Kenneth Rich
    • 4
  • Barry Lester
    • 5
  • Stephen A. Spector
    • 6
  • Ram Yogev
    • 7
  • George R. SeageIII
    • 1
  1. 1.Department of EpidemiologyHarvard School of Public HealthBostonUSA
  2. 2.Eunice Kennedy Shriver National Institute of Child Health and Human DevelopmentNIHBethesdaUSA
  3. 3.Center for Biostatistics in AIDS ResearchHarvard School of Public HealthBostonUSA
  4. 4.Department of PediatricsUniversity of Illinois at ChicagoChicagoUSA
  5. 5.Center for the Study of Children at RiskThe Warren Alpert Medical School of Brown University and Women and Infants HospitalProvidenceUSA
  6. 6.Department of Pediatrics, Division of Infectious DiseasesUniversity of California, San DiegoLa JollaUSA
  7. 7.Section of Pediatric, Adolescent and Maternal HIV InfectionChildren’s Memorial HospitalChicagoUSA

Personalised recommendations